lamivudine has been researched along with Hematologic Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, FW; Coyle, L; Jones, BE; Pattullo, V | 1 |
| Aloe-Spiriti, MA; Angeletti, S; Cipriani, P; Cox, MC; Delle Fave, G; Gallina, S; Leone, F; Marignani, M; Monarca, B; Veggia, B | 1 |
| Balducci, M; Clementi, M; Manzin, A; Petrelli, E; Pieretti, C; Rocchi, MB | 1 |
3 other study(ies) available for lamivudine and Hematologic Diseases
| Article | Year |
|---|---|
Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Topics: Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Guanine; Hematologic Diseases; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Patient Selection; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Virus Activation | 2013 |
Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?
Topics: Choice Behavior; Disease Management; Follow-Up Studies; Hematologic Diseases; Hepatitis B, Chronic; Humans; Lamivudine | 2009 |
Lamivudine treatment failure in preventing fatal outcome of de novo severe acute hepatitis B in patients with haematological diseases.
Topics: Acute Disease; Adult; Aged; Child; Cross Infection; Disease Outbreaks; Fatal Outcome; Female; Hematologic Diseases; Hepatitis B; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Failure | 2001 |